X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1869) 1869
Book Review (391) 391
Publication (142) 142
Book Chapter (29) 29
Dissertation (10) 10
Conference Proceeding (9) 9
Book / eBook (1) 1
Data Set (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1325) 1325
humans (1118) 1118
non-inferiority (912) 912
non-inferiority trial (655) 655
female (438) 438
male (421) 421
treatment outcome (396) 396
clinical trials (382) 382
middle aged (312) 312
open-label (309) 309
pharmacology & pharmacy (306) 306
double-blind (281) 281
statistics & probability (281) 281
adult (240) 240
aged (235) 235
infectious diseases (233) 233
analysis (190) 190
drug therapy (186) 186
efficacy (179) 179
oncology (177) 177
care and treatment (176) 176
hiv infections - drug therapy (174) 174
equivalence (173) 173
medicine, research & experimental (168) 168
research design (161) 161
cardiac & cardiovascular systems (153) 153
sample size (152) 152
clinical-trials (143) 143
immunology (142) 142
medicine, general & internal (138) 138
safety (138) 138
confidence intervals (136) 136
research (136) 136
non-inferiority trials (130) 130
mathematical & computational biology (128) 128
patients (124) 124
abridged index medicus (123) 123
hiv (118) 118
studies (118) 118
design (116) 116
data interpretation, statistical (115) 115
public, environmental & occupational health (113) 113
models, statistical (110) 110
medical informatics (109) 109
therapy (107) 107
medical research (106) 106
risk factors (102) 102
human immunodeficiency virus--hiv (101) 101
randomized controlled-trial (101) 101
drug-eluting stents (100) 100
randomized controlled trials as topic (99) 99
time factors (98) 98
diabetes mellitus, type 2 - drug therapy (97) 97
antiretroviral therapy (96) 96
endocrinology & metabolism (96) 96
health aspects (96) 96
randomized-trial (96) 96
medicine (93) 93
cancer (91) 91
usage (91) 91
initial treatment (90) 90
comparative analysis (88) 88
internal medicine (88) 88
noninferiority (88) 88
thrombosis (88) 88
diabetes (86) 86
microbiology (86) 86
follow-up (84) 84
double-blind method (82) 82
statistics (82) 82
dosage and administration (81) 81
issues (81) 81
type 2 diabetes (79) 79
young adult (79) 79
medicine & public health (78) 78
percutaneous coronary intervention (78) 78
drug therapy, combination (76) 76
meta-analysis (76) 76
follow-up studies (75) 75
anti-hiv agents - therapeutic use (73) 73
surgery (73) 73
tenofovir (73) 73
adolescent (72) 72
superiority (72) 72
hiv infections - virology (71) 71
risk (71) 71
antiretroviral drugs (70) 70
pharmacology (70) 70
biodegradable polymer (69) 69
outcomes (69) 69
animals (68) 68
clinical trials as topic (68) 68
co-formulated elvitegravir (68) 68
non‐inferiority (68) 68
trials (68) 68
chemotherapy (67) 67
prospective studies (67) 67
randomized controlled trials as topic - methods (67) 67
hypoglycemic agents - therapeutic use (66) 66
aged, 80 and over (65) 65
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1836) 1836
German (30) 30
French (22) 22
Spanish (10) 10
Korean (5) 5
Italian (4) 4
Japanese (4) 4
Chinese (2) 2
Polish (2) 2
Georgian (1) 1
Portuguese (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Hepatology, ISSN 0168-8278, 2014, Volume 61, Issue 4, pp. 792 - 798
Background & Aims: Both corticosteroid and pentoxifylline reduce short-term mortality in severe alcoholic hepatitis. However, few studies have directly... 
Pentoxifylline | Corticosteroid | Alcoholic hepatitis | Non-inferiority trial
Journal Article
DIABETES CARE, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 355 - 364
OBJECTIVE To assess the efficacy/safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, compared with glimepiride over 104 weeks in patients with... 
PLACEBO | ADD-ON | MONOTHERAPY | HYPERGLYCEMIA | SULFONYLUREA | EFFICACY | DAPAGLIFLOZIN | SAFETY | ENDOCRINOLOGY & METABOLISM | NON-INFERIORITY TRIAL | MELLITUS
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 08/2018, Volume 36, Issue 23, pp. 2452 - 2452
Journal Article
NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 07/2018, Volume 379, Issue 4, pp. 396 - 397
Journal Article
10/2011
Non-inferiority clinical trials are being performed with an increasing frequency now-a-days, because it helps in finding a new treatment that have... 
Assay sensitivity | non-inferiority | bio-creep | clinical trials | sample size
Web Resource
LANCET ONCOLOGY, ISSN 1470-2045, 08/2016, Volume 17, Issue 8, pp. 1061 - 1069
Background Studies have reported a low alpha/beta ratio for prostate cancer, suggesting that hypofractionation could enhance the biological tumour dose without... 
NON-INFERIORITY | THERAPY | DOSE-RESPONSE | ONCOLOGY | CONFORMAL RADIOTHERAPY | INTENSITY-MODULATED RADIOTHERAPY | COMPARING 68 GY | ACUTE TOXICITY | CHHIP TRIAL | OUTCOMES | FAILURE
Journal Article
Annals of Oncology, ISSN 0923-7534, 05/2018, Volume 29, Issue 5, pp. 1220 - 1226
Abstract Background Paclitaxel is currently only available as an intravenous (i.v.) formulation. DHP107 is a novel oral formulation of lipid ingredients and... 
DHP107 | Oral paclitaxel | Gastric cancer | Non-inferiority | Progression free survival
Journal Article
LANCET ONCOLOGY, ISSN 1470-2045, 09/2015, Volume 16, Issue 11, pp. 1193 - 1224
Surgery is essential for global cancer care in all resource settings. Of the 15.2 million new cases of cancer in 2015, over 80% of cases will need surgery,... 
MIDDLE-INCOME COUNTRIES | UNIVERSAL HEALTH COVERAGE | ONCOLOGY | SENTINEL-NODE BIOPSY | SUB-SAHARAN AFRICA | SQUAMOUS-CELL CARCINOMA | NON-INFERIORITY TRIAL | RANDOMIZED CONTROLLED-TRIAL | SINGLE-INSTITUTION EXPERIENCE | STANDARD AXILLARY TREATMENT | TOTAL MESORECTAL EXCISION
Journal Article
Statistics in medicine, ISSN 0277-6715, 5/2015, Volume 34, Issue 11, pp. 1834 - 1840
The question of when to adjust for important prognostic covariates often arises in the design of clinical trials, and there remain various opinions on whether... 
covariates | clinical trials | randomization | Non-inferiority
Journal Article
Revue de Medecine Interne, ISSN 0248-8663, 05/2018, Volume 39, Issue 5, pp. 352 - 359
Non-inferiority and equivalence trials aim to promote new treatments that are not expected to be superior to existing ones in a given indication. In order to... 
Clinical trials | Equivalence | Methodology | Non-inferiority
Journal Article
JAMA, ISSN 0098-7484, 12/2012, Volume 308, Issue 24, pp. 2594 - 2604
Journal Article
Oncotarget, ISSN 1949-2553, 02/2019, Volume 10, Issue 11, pp. 1209 - 1216
Adjuvant chemotherapy has an indisputable value for early breast cancer patients. Anthracycline and taxane-based regimens (TaxAC) have not been proven superior... 
Journal Article
Journal of Investigative Dermatology, ISSN 0022-202X, 03/2018, Volume 138, Issue 3, pp. 527 - 533
For the treatment of superficial basal cell carcinoma, a prospective, noninferiority, randomized controlled multicenter trial with 601 patients showed that 5%... 
NON-INFERIORITY | SURGERY | SINGLE-BLIND | NONINFERIORITY | DISCRETE-CHOICE EXPERIMENT | FOLLOW-UP | FLUOROURACIL | SINS | 5-PERCENT CREAM | SKIN-CANCER | DERMATOLOGY | Index Medicus
Journal Article
NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 11/2013, Volume 369, Issue 20
Journal Article
DIABETES CARE, ISSN 0149-5992, 07/2013, Volume 36, Issue 7, pp. 2126 - 2132
There is no question that incretin-based glucose-lowering medications have proven to be effective glucose-lowering agents. Glucagon-like peptide 1 (GLP-1)... 
NON-INFERIORITY | DIPEPTIDYL PEPTIDASE-4 INHIBITORS | THYROID C-CELLS | GLUCAGON-LIKE PEPTIDE-1 | GLP-1 ANALOG LIRAGLUTIDE | RECEPTOR AGONISTS | ENDOCRINOLOGY & METABOLISM | POOLED ANALYSIS | CARDIOVASCULAR SAFETY | ACUTE-PANCREATITIS | TYPE-2 DIABETES-MELLITUS
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2018, Volume 36, Issue 7, pp. 674 - 681
Purpose Conflicting results are reported for maintenance treatment with bevacizumab during chemotherapy-free intervals (CFI) in metastatic colorectal cancer... 
NON-INFERIORITY | SURVIVAL | 1ST-LINE TREATMENT | LEUCOVORIN | THERAPY | ONCOLOGY | IRINOTECAN | OPEN-LABEL | OXALIPLATIN | FOLFIRI PLUS BEVACIZUMAB | FLUOROURACIL | Life Sciences | Cancer
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.